MC

MC (monocytes control) is an autologous cell therapy consisting of monocytes derived from a patient's own peripheral blood mononuclear cells (PBMC). Developed by Aivita Biomedical, Inc., it serves as the randomized control/placebo arm in Phase 2 clinical trials (such as NCT02033616) evaluating AVOVA-1, an autologous dendritic cell therapy. In these trials, patients with Stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal carcinoma receive either the active dendritic cell treatment or the MC control via subcutaneous injection following standard debulking surgery and primary chemotherapy. The MC control is intended to provide a comparable cellular injection without the specific antigen-loading and maturation processes applied to the active treatment arm, allowing for a double-blind assessment of overall survival and disease progression.

Other names

autologous monocytesmonocytes controlautologous peripheral blood mononuclear cellsPBMC